Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 17 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... February 4, 2026 Pastor Opens Homeless Shelter And Moves In To Raise Money For... December 29, 2021 Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 Load more HOT NEWS FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... 7 ways we’ve influenced progress in lung cancer Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors
